Bio-Thera Solutions has closed patient enrollment ahead of schedule for a pivotal Phase 2/3 clinical trial in China of its investigational therapy BAT4406F due to the treatment’s “compelling efficacy” for neuromyelitis optica spectrum disorder (NMOSD). The decision is based on a recommendation from an Independent Data Monitoring Committee…
China
Soliris (eculizumab) has been approved in China to treat adults with neuromyelitis optica spectrum disorder, known as NMO or NMOSD, who test positive for antibodies against the aquaporin-4 (AQP4) protein. The therapy — which works to reduce the risk of relapse and ease inflammation among patients — was approved…
People who develop neuromyelitis optica spectrum disorder (NMOSD) later in life may go on to experience worse outcomes than those who have early-onset disease, a study in China has found. Worse outcomes included a higher frequency of inflammation of the thoracic spinal cord during relapses, more brain lesions and…
The Illness Challenge Foundation (ICF) sponsored the second annual Asia-Pacific NMOSD Patient Day in Beijing, China, to increase awareness and improve care for those living with neuromyelitis optica spectrum disorder (NMOSD). The May 25 event brought together NMOSD patients, neurologists and other healthcare professionals, and representatives from a variety…
Recent Posts
- Embracing an opportunity for advocacy on Rare Disease Day
- Cognitive issues affect nearly 1 in 3 with NMOSD, study finds
- With AI’s expanded use in healthcare settings, I’m excited for the future
- Pure oxygen therapy may reduce inflammation in NMOSD: Study
- How NMOSD has quietly shaped my experience of pain